Cargando…

Experiences of children and adolescents living with achondroplasia and their caregivers

BACKGROUND: Achondroplasia, caused by a pathogenic variant in the fibroblast growth factor receptor 3 gene (FGFR3), leads to significant multisystem complications across the lifespan that may affect the health‐related quality of life (HRQoL) of individuals and families living with the condition. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shediac, Renée, Moshkovich, Olga, Gerould, Heather, Ballinger, Rachel, Williams, Agnes, Bellenger, M. Alex, Quinn, Jennifer, Hoover‐Fong, Julie, Mohnike, Klaus, Savarirayan, Ravi, Kelly, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000943/ https://www.ncbi.nlm.nih.gov/pubmed/35138050 http://dx.doi.org/10.1002/mgg3.1891

Ejemplares similares

Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia
por: Chan, Ming Liang, et al.
Publicado: (2021)

PSAT103 Qualitative Research in Children with Achondroplasia and Parents of Children with Achondroplasia: Medical Challenges and Impacts
por: Muslimova, Elena, et al.
Publicado: (2022)

Hearing loss in Norwegian adults with achondroplasia
por: Fredwall, Svein O., et al.
Publicado: (2021)

Optimal management of complications associated with achondroplasia
por: Ireland, Penny J, et al.
Publicado: (2014)

Burden and Treatment of Achondroplasia: A Systematic Literature Review
por: Murton, Molly C., et al.
Publicado: (2023)

Birth prevalence of achondroplasia: A systematic literature review and meta‐analysis
por: Foreman, Pamela K., et al.
Publicado: (2020)

Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study
por: Maghnie, Mohamad, et al.
Publicado: (2023)

SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2020)

SUN-093 Prospective Clinical Assessment Study in Children with Achondroplasia: The PROPEL Trial
por: Savarirayan, Ravi, et al.
Publicado: (2020)

Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations
por: Cormier-Daire, Valerie, et al.
Publicado: (2022)

Current knowledge of medical complications in adults with achondroplasia: A scoping review
por: Fredwall, Svein O., et al.
Publicado: (2019)

Impact of achondroplasia on Latin American patients: a systematic review and meta-analysis of observational studies
por: Fano, Virginia, et al.
Publicado: (2022)

Quality of life of children with achondroplasia and their parents - a German cross-sectional study
por: Witt, Stefanie, et al.
Publicado: (2019)

Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies
por: Savarirayan, Ravi, et al.
Publicado: (2022)

Cardiovascular risk factors and body composition in adults with achondroplasia
por: Fredwall, Svein O., et al.
Publicado: (2020)

Parents’ Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia
por: NiMhurchadha, Sinead, et al.
Publicado: (2023)

Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study
por: Savarirayan, Ravi, et al.
Publicado: (2022)

Australian guidelines for the management of children with achondroplasia
por: Tofts, Louise J, et al.
Publicado: (2023)

Correction to: Cardiovascular risk factors and body composition in adults with achondroplasia
por: Fredwall, Svein O., et al.
Publicado: (2021)

Obstructive sleep apnea in Norwegian adults with achondroplasia: a population-based study
por: Fredwall, Svein O., et al.
Publicado: (2021)

The first European consensus on principles of management for achondroplasia
por: Cormier-Daire, Valerie, et al.
Publicado: (2021)

Optimising care and follow-up of adults with achondroplasia
por: Fredwall, Svein, et al.
Publicado: (2022)

PSAT102 Qualitative Research in Children and Parents of Children with Achondroplasia to Cognitively Debrief Three Patient-Reported Outcome Measures and Confirm the Content Validity of a Clinical-Assessed Measure
por: Muslimova, Elena, et al.
Publicado: (2022)

High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study
por: Fredwall, Svein O., et al.
Publicado: (2020)

Persistent and Stable Growth Promoting Effects of Vosoritide in Children With Achondroplasia for up to 2 Years: Results From the Ongoing Phase 3 Extension Study
por: Savarirayan, Ravi, et al.
Publicado: (2021)

Correction to: High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study
por: Fredwall, Svein O., et al.
Publicado: (2020)

Fat infiltration in the thigh muscles is associated with symptomatic spinal stenosis and reduced physical functioning in adults with achondroplasia
por: Fredwall, Svein O., et al.
Publicado: (2023)

Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States
por: Hoover-Fong, Julie E., et al.
Publicado: (2021)

Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study
por: Savarirayan, Ravi, et al.
Publicado: (2021)

Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study—a multi-center retrospective cohort study of achondroplasia in the US
por: Hoover-Fong, Julie E., et al.
Publicado: (2021)

Achondroplasia
por: Hunter, Richard H.
Publicado: (1933)

Achondroplasia
por: Flemming, Charles E. S.
Publicado: (1899)

PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies
por: Muslimova, Elena, et al.
Publicado: (2022)

PSAT105 Evaluation of Body Mass Index and Metabolic Parameters in Children with Achondroplasia Participating in the PROPEL Study
por: Rogoff, Daniela, et al.
Publicado: (2022)

Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia
por: Prickett, Timothy C. R., et al.
Publicado: (2021)

The Antiquity of Achondroplasia
por: Bleyer, Adrirn
Publicado: (1940)

RF26 | PMON326 Medical History of Children Enrolled in PROPEL: A Prospective Clinical Assessment Study in Children with Achondroplasia
por: Irving, Melita, et al.
Publicado: (2022)

European Achondroplasia Forum guiding principles for the detection and management of foramen magnum stenosis
por: Irving, Melita, et al.
Publicado: (2023)

THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials
por: Savarirayan, Ravi, et al.
Publicado: (2023)

LBMON196 A Randomized Controlled Trial Of Vosoritide In Infants And Toddlers With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s34816m51s1mi5882e31rh4o1k